See more : Turkiye Garanti Bankasi A.S. (TKGZY) Income Statement Analysis – Financial Results
Complete financial analysis of Phathom Pharmaceuticals, Inc. (PHAT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Phathom Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Carrefour SA (CRERF) Income Statement Analysis – Financial Results
- POSaBIT Systems Corporation (POSAF) Income Statement Analysis – Financial Results
- Orient Cement Limited (ORIENTCEM.NS) Income Statement Analysis – Financial Results
- Ranger Oil Corporation (ROCC) Income Statement Analysis – Financial Results
- CTPartners Executive Search Inc. (CTPR) Income Statement Analysis – Financial Results
Phathom Pharmaceuticals, Inc. (PHAT)
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 682.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 167.00K | 620.00K | 521.00K | 300.00K | 8.00K | 0.00 |
| Gross Profit | 515.00K | -620.00K | -521.00K | -300.00K | -8.00K | 0.00 |
| Gross Profit Ratio | 75.51% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 49.90M | 71.44M | 72.34M | 98.15M | 99.27M | 20.00K |
| General & Administrative | 0.00 | 101.00M | 62.74M | 27.52M | 6.94M | 1.21M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 117.93M | 101.00M | 62.74M | 27.52M | 6.94M | 1.21M |
| Other Expenses | 0.00 | -110.00K | -2.06M | -8.00K | -49.56M | -50.00K |
| Operating Expenses | 167.83M | 172.44M | 135.08M | 125.67M | 106.22M | 1.23M |
| Cost & Expenses | 167.99M | 172.44M | 135.08M | 125.67M | 106.22M | 1.23M |
| Interest Income | 7.88M | 2.13M | 41.00K | 1.09M | 1.09M | 0.00 |
| Interest Expense | 41.97M | 27.31M | 6.79M | 4.58M | 4.18M | 13.00K |
| Depreciation & Amortization | 575.00K | 620.00K | 521.00K | 300.00K | 8.00K | 1.23M |
| EBITDA | -159.05M | -171.82M | -134.56M | -124.19M | -250.95M | -50.00K |
| EBITDA Ratio | -23,320.97% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -167.31M | -172.44M | -135.08M | -125.67M | -106.22M | -1.23M |
| Operating Income Ratio | -24,532.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -34.28M | -25.28M | -8.80M | -3.40M | -148.92M | -63.00K |
| Income Before Tax | -201.59M | -197.72M | -143.88M | -129.07M | -255.13M | -1.29M |
| Income Before Tax Ratio | -29,558.94% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 25.28M | 4.21M | 4.25M | -45.39M | 13.00K |
| Net Income | -201.59M | -223.01M | -148.09M | -133.32M | -209.74M | -1.29M |
| Net Income Ratio | -29,558.94% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.93 | -5.70 | -4.00 | -4.01 | -8.48 | -0.15 |
| EPS Diluted | -3.93 | -5.70 | -4.00 | -4.01 | -8.48 | -0.15 |
| Weighted Avg Shares Out | 51.29M | 39.12M | 37.00M | 33.23M | 24.73M | 8.58M |
| Weighted Avg Shares Out (Dil) | 51.29M | 39.12M | 37.00M | 33.23M | 24.73M | 8.58M |
Phathom (PHAT) Up 8% on Erosive Esophagitis Drug's CRL Update
Phathom Pharmaceuticals (PHAT) announces a regulatory update regarding vonoprazan for the treatment of erosive esophagitis and H. pylori infection.
Here's Why Phathom Pharmaceuticals, Inc. (PHAT) Is a Great 'Buy the Bottom' Stock Now
Phathom Pharmaceuticals, Inc. (PHAT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates...
All You Need to Know About Phathom Pharmaceuticals, Inc. (PHAT) Rating Upgrade to Buy
Phathom Pharmaceuticals, Inc. (PHAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Phathom's stock falls after receiving FDA letters
Shares of Phathom Pharmaceuticals Inc. PHAT, -0.60% tumbled about 23% in premarket trading on Friday, the day after the company said it received complete response letters from the Food and Drug Administration related to vonoprazan, which is approved for two...
Why Shares of Phathom Pharmaceutical Jumped This Week
Investors are reading between the lines to see if the company is fixing its problems regarding its lead therapy.
Phathom (PHAT) Down on Regulatory Update on Vonoprazan NDA
Phathom Pharmaceuticals, Inc. (PHAT) declines as the FDA decides to not take any action on Phathom's new drug application (NDA) for vonoprazan for treating erosive esophagitis.
Phathom Pharma: Approved Drugs, Upcoming PDUFA, Smallish Addressable Market
PHAT, a Takeda spinoff, has a drug approved in H. pylori. The same drug has a PDUFA in a GERD subtype.
Phathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
FLORHAM PARK, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of the management team will present virtually...
Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of the management team will participate in...
Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting
FLORHAM PARK, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), an innovative biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the company will present findings from multiple studies at Digestive...
Source: https://incomestatements.info
Category: Stock Reports